Since the regulation of vascular function involves complex mutual interactions between NO synthase (NOS) and cyclooxygenase (COX) products, we examined the contribution of NO and prostanoids derived from the COX pathway in modulating aortic baroreceptor resetting during an acute (30 min) increase in arterial pressure in anesthetized rats. Increase in pressure was induced either by administration of the nonselective NOS inhibitor N g -nitro-L-arginine-methyl ester (L-NAME) or aortic coarctation (COA) with or without treatment with the COX inhibitor indomethacin (INDO) or the selective neuronal NOS inhibitor 1-(2-trifluoromethylphenyl) imidazole (TRIM). The activity of the aortic depressor nerve and arterial pressure were simultaneously recorded, and the degree of resetting was determined by the shift of the pressure-nerve activity curve using the ratio [ systolic pressure at 50% of maximum baroreceptor activity/ systolic pressure] x 100. The magnitude of pressure rise was similar in the different groups (59±6, 53±5, 53±5, 45±5, 49±3 and 41±3 mmHg for COA, L-NAME, INDO+COA, INDO+L-NAME, TRIM+COA and TRIM+INDO+COA, respectively, P=0.27).
INTRODUCTION
Aortic baroreceptors are mechanoreceptors stimulated by the stretch of the vessel wall leading to reflex regulation of the cardiovascular system. Therefore, baroreceptor activity promptly buffers arterial pressure fluctuations; nevertheless, when a change in arterial pressure is maintained, the baroreceptors quickly reset to the new hypotensive or hypertensive level (3, 13) .
Although arterial pressure is the main determinant of the baroreceptor activity and resetting to new levels of arterial pressure, baroreceptor sensitivity to changes in pressure can be modulated by autacoids (4, 5) . Stretching of vessel wall not only activates the baroreceptors, but also alters the release of endothelial factors, such as nitric oxide (NO) and cyclooxygenase (COX)-derived prostanoids, mostly prostacyclin (PGI 2 ) (21) , which may affect baroreceptor activity and/or sensitivity to detect changes in arterial pressure (6) .
In isolated carotid sinus from anesthetized rabbits, COX inhibitors attenuated and PGI 2 enhanced baroreceptor sensitivity to increases in arterial pressure without altering the pressure-diameter relation, suggesting a role for prostanoids in modulating baroreceptor function (7) . On the other hand, NO may modulate baroreceptor function by decreasing the tension imposed on baroreceptor nerve endings by means of vasodilatation and also by exerting a direct effect on baroreceptor nerve terminals.
Indeed, endothelial and neuronal NO synthase (NOS)-derived NO could be involved in the modulation of baroreceptor resetting and sensitivity (11, 15) . In isolated rabbit carotid sinus preparations, NO or NO donors elicited inhibition of baroreceptor activity that was not related to NO-induced vasodilatation (18) . In contrast, carotid sinus baroreceptor function in cats was insensitive to changes in the supply of endogenous or exogenous NO (30) .
Most of the experimental evidence demonstrating an influence of NOS or COX products on baroreceptor activity has been generated by studies in isolated carotid sinus preparations, and the potential contribution of NO and prostanoids has been examined separately. In addition, it has become increasingly evident that complex mutual interactions may exist between NOS and COX products. For example, high levels of NO 4 may inhibit or augment the release of PGI 2 in endothelial cells (9, 26) and chronic NO inhibition results in the activation of cyclooxygenase (2, 8) . Therefore, the aim of the present study was to investigate in vivo a possible role of NO and prostanoids in modulating aortic baroreceptor resetting during sustained increase of arterial pressure.
To achieve this purpose, we examined the effect of the non-selective NOS inhibitor N g -nitro-L-arginine methyl ester (L-NAME), the selective neuronal NOS inhibitor 1-(2-trifluoromethylphenyl) imidazole (TRIM) (10) , and the COX inhibitor indomethacin on baroreceptor activity. In contrast to L-NAME, TRIM and indomethacin do not change arterial pressure by themselves; therefore, to examine the potential contribution of neuronal NOS-or COX-derived products on baroreceptor resetting, the increase in arterial pressure was induced by controlled aortic coarctation.
MATERIALS AND METHODS

Animals
Normotensive male Wistar rats, weighing 250 to 300 g were used. Animals were kept under controlled temperature and humidity, and exposed to a 12 hr dark/light cycle.
They were allowed food and water ad libitum. All experimental procedures were in accordance with guiding principles of the American Physiological Society and approved by our Institutional Review Board.
Surgical Procedures, Cardiovascular and Nerve Activity Recordings
The procedures for recording the whole-nerve activity from the aortic depressor nerve have been described previously (1, 25) . The rats were anesthetized with sodium pentobarbital (40 mg/kg, ip) and catheters were inserted into the right carotid artery for measurement of arterial pressure, into the right femoral artery for withdrawal and reinfusion of blood and into the femoral vein for administration of drugs. A pneumatic cuff was placed around the abdominal aorta immediately below the diaphragm, in order to promote rapid and sustained increase of arterial pressure to trigger baroreceptor resetting. The left aortic nerve was identified in the neck, carefully isolated from connective tissue, placed on a bipolar stainless steel pair of electrodes and carefully 5 insulated with a silicon molding material (President-Coltene). The nerve activity was amplified (1000 to 3000 x) and band pass filtered (100 Hz -3 kHz) using a differential high impedance amplifier (Princeton Applied Research, model 113) and monitored on an oscilloscope (model 5113, Tektronics, Inc) and a loudspeaker. This activity was sampled (10 kHz), simultaneously with the pulsatile carotid pressure in an IBM/PC equipped with an analog to digital interface (Aqdados, Lynx Technology, São Paulo, SP, Brazil).
Experimental Protocol
After basal recordings of arterial pressure and ADN activity, baroreceptor firing range was determined as follows: the arterial pressure was decreased, by means of controlled hemorrhage, until complete cessation of baroreceptor activity and quickly raised, by reinfusion of blood associated with aortic constriction until the maximal ADN activity was achieved. After determining a pressure nerve activity curve under basal condition, a prompt and sustained (30 min period) increase in arterial pressure was carried out by means of either aortic constriction, caused by the pneumatic cuff, or by means of the hypertensive effect of L-NAME administration (70 mg/kg, iv). At the end of the 30 min period, another pressure-nerve activity curve was determined under the hypertensive condition.
The role of prostanoids on baroreceptor activity was examined in animals that received indomethacin (5 mg/kg, iv) 10 min before aortic constriction or received L-NAME. Likewise, a role for NO derived from neuronal NOS was examined in animals pretreated with TRIM (30 mg/kg, iv) 10 min before aortic constriction. Accordingly, arterial pressure and baroreceptor activity were recorded in rats that received intravenous administration of L-NAME alone (n=7), indomethacin plus L-NAME (n=6), and indomethacin (n=6), TRIM (n=6) or indomethacin plus TRIM (n=6) combined with aortic coarctation. Normotensive rats treated with saline (0.1 mL, iv, n=6) and submitted to aortic constriction to induce hypertension were used as controls. The degree of aortic constriction was adjusted to produce increases in pressure similar to the increases induced by L-NAME. The NOS and COX inhibitors were purchased from Sigma Co. (St.
Louis, MO, USA) and dissolved in normal saline. 6 
Data analysis
Raw aortic nerve activity (voltage) was rectified and integrated on a pulse length basis providing beat -by -beat series of mean nerve activity. To compare the whole multifiber ADN activity among different rats, the integrated activity was normalized as a function of the maximal activity achieved during the baroreceptor-firing range assessment described before. Normalized ADN activity was plotted against beat-by-beat values of systolic arterial pressure (SAP) to obtain pressure-nerve activity curves. The curves were fitted by a 4-parameters sigmoidal regression based on the Levemberg-Marquadt algorithm (16) , and the maximum gain (the maximal first derivative of the curve) and the SAP at 50% of maximal nerve activity (SAP 50 ) were obtained. To avoid the influence of hysteresis, only values obtained during rise in arterial pressure (reinfusion of blood)
were used. The ratio between the shift in SAP 50 and the shift in SAP due to the hypertensive stimulus was used as an index of the degree of baroreceptor resetting as described elsewhere (27) .
Statistical Analysis
Results are presented as mean ± SEM. The values of baroreceptor maximum gain were log-transformed and compared among groups, before and after the hypertensive stimulus, by means of the parametric two-way analysis of variance (ANOVA) for repeated measures, with the post-hoc Tukey test for multiple comparisons. The nonparametric Kruskal-Wallis one-way ANOVA followed by Dunnet's test was used to compare the extent of resetting as well as the changes in the conditioning pressure ( MAP) among the groups. Changes were considered statistically significant at P<0.05.
RESULTS
Aortic coarctation or L-NAME administration induced a rapid and sustained increase in mean arterial pressure of similar magnitude in all groups studied (Figure 1 ). Figure 2 shows the pressure-nerve activity curve before (basal condition) and after 30 min of hypertensive stimulus in a rat submitted to aortic constriction alone. In Table 1 . All groups, except that treated with L-NAME, showed a parallel rightward shift of the curves, indicating that the baroreceptor gain did not change during the hypertensive stimulus. In the group treated with L-NAME, however, the rightward shift of the pressure-nerve activity curve not only did not occur in a parallel manner, but also indicated an increase in baroreceptor sensitivity to detect increases in arterial pressure when compared to control period. In animals pre-treated with indomethacin, L-NAME failed to affect baroreceptor gain. Indomethacin alone had no significant effect on baroreceptor gain. degree of resetting (greater baroreceptor activity) in L-NAME treated rats as compared to aortic coarctation alone (Fig. 3) . The degree of resetting calculated by the ratio SAP 50 / SAP determined by the pressure-nerve activity curve in all groups is presented in Figure 4 . A similar hypertensive stimulus elicited a smaller degree of resetting in animals treated with either NOS inhibitor (L-NAME or TRIM) as compared to aortic coarctation alone. In addition, Figure 4 also shows that the effect of L-NAME or TRIM was abolished in the presence of indomethacin, although indomethacin alone did not significantly affect the degree of baroreceptor resetting during aortic constriction.
DISCUSSION
The major finding of the present study is that blockade of NOS with L-NAME (a non-specific inhibitor of NOS) or TRIM (a specific inhibitor of neuronal NOS) attenuated the rapid resetting of the aortic baroreceptors to a prompt and sustained increase in arterial pressure. The maximum gain, which represents baroreceptor sensitivity, was affected by L-NAME, but not by TRIM, suggesting that NO coming from a source distinct 8 from neuronal NOS pathway decreases baroreceptor sensitivity. Another novel finding is that either L-NAME or TRIM failed to affect baroreceptor activity in indomethacin pretreated rats, suggesting that NO contributes to the rapid baroreceptor resetting through a COX-dependent mechanism.
As baroreceptor resetting to hypertensive levels can be defined as a decrease in baroreceptor activity at a constant pressure, we can postulate that any substance inducing a smaller degree of resetting is actually increasing baroreceptor activity. The fact that rats treated with either NOS inhibitors, L-NAME or TRIM, exhibited a decrease in the degree of resetting strongly suggests that inhibition of baroreceptor activity was indeed dependent on NO production. This interpretation is in line with studies showing that administration of NO or NO donors to carotid sinus and carotid bodies isolated from rabbits or cats inhibits the activity of baroreceptor and chemoreceptor nerves (18, 23, 24) . The functional role of endogenous NO and its ability to chronically inhibit baroreceptor activity and resetting of the baroreceptor function curve to higher pressures were also demonstrated in rabbits using adenoviral-mediated gene transfer of eNOS to carotid sinus adventitia (19) . The fact that in the present study both non-selective (L-NAME) and neuronal NOS (TRIM) inhibitors induced a comparable decrease in the degree of baroreceptor resetting to higher pressure strongly suggests that NO from neuronal source is the responsible for this effect. This interpretation is supported by the fact that TRIM administration did not affect blood pressure (10) , suggesting inhibition of neuronal NOS without influencing endothelial NOS. In fact, immunoreactivity to neuronal isoform of NOS has been detected in baroreceptor neurons (11, 15) , raising the possibility that NO may act as an autocrine regulator of baroreceptor nerve activity. In contrast, only L-NAME affected baroreceptor sensitivity (gain) after a 30-min period of maintained increase in arterial pressure, suggesting that NO from non-neuronal sources, mostly likely from endothelial NOS, is responsible for this effect. The finding that L-NAME increased baroreceptor sensitivity is in agreement with that obtained in rabbit isolated carotid sinus showing that NO or NO donors diminish baroreceptor gain through a mechanism independent of vascular relaxation (18) .
In contrast to the diminished extent of baroreceptor resetting to a prompt and maintained hypertension induced by L-NAME observed in the present study, a greater 9 extent of resetting to hypertensive levels was described when another NOS inhibitor, N G -nitro-L-arginine (L-NOARG), was used (27) . It is worth mentioning that the increase in arterial pressure in that study was induced in a ramp progression by L-NOARG, attaining a peak value in approximately 25-min period, while in the present study the increase in pressure induced by L-NAME was faster (2-3 min to reach the plateau) due to the characteristic action of this drug. It is accepted that L-NAME represents a prodrug lacking NOS inhibitory activity unless it is hydrolyzed to L-NOARG and bioactivation of L-NAME is markedly accelerated in tissues such as blood or vascular endothelium (22) . Thus, in view of this discrepancy, it is reasonable to speculate that the type of stimulus can affect the contribution of the factors that modulate baroreceptor activity. It is well documented that in anesthetized dogs, carotid sinus nerve activity increases abruptly and then resets (decreases) during the sustained increase in static pressure, while the resetting is attenuated during the increase in the mean level of pulsatile pressure, providing support to the notion that the type of stimulus affects the degree of resetting of the baroreceptors (3).
Stretching of the vessel wall not only stimulates the endothelium to release NO, but also a number of substances, including prostanoids, which may act as paracrine factors modulating baroreceptor activity. Indeed, PGI 2 , which is the major prostanoid produced by the vascular endothelium, contributes to the activation of baroreceptors and enhances baroreflex inhibition of lumbar sympathetic nerve activity in rabbits (17) while indomethacin reduces acute baroreceptor resetting in dogs (28) . An impaired production of prostanoids has been described to contribute to decreased baroreceptor activity in hypertensive rabbits (29) . In the present study, however, COX inhibition with indomethacin did not affect baroreceptor sensitivity or resetting to hypertension, suggesting that prostanoids do not play an important role modulating baroreceptor function in vivo. This interpretation is consistent with data obtained from healthy humans showing that baroreflex sensitivity was not impaired by acute COX inhibition (20) . This finding is of importance because of the widespread use of nonsteroidal antiinflammatory drugs, which are powerful inhibitors of COX. Interestingly, inhibition of COX abolished the effect induced by either NOS inhibitors (L-NAME or TRIM) on the degree of baroreceptor resetting to hypertension. These findings are consistent with the 10 notion that there is an interaction between the NOS and COX dependent products in the modulation of baroreceptor activity in vivo. Since indomethacin alone did not affect baroreceptor activity, it is reasonable to think that COX-derived products do not influence NOS activity. On the contrary, one explanation could be that NO exerts a negative feedback on COX mediated prostanoids synthesis; accordingly, the effect of COX derived products on baroreceptor activity became evident only after NOS inhibition. It is noteworthy that NO has been shown to inhibit oxidation by COX in enzymatic studies in vitro (12) . Another possible explanation is that NOS inhibition could induce a shift in the synthesis or in the effects of COX products (14) in favor of prostanoids that have the ability to increase baroreceptor activity. Nevertheless, when COX and NOS are inhibited, other products from the arachidonic acid metabolism may affect baroreceptor function; therefore, more complex and indirect interactions involving these metabolites cannot be ruled out.
In conclusion, our study in the rat indicates that NO may contribute to rapid baroreceptor resetting during acute hypertension and affect baroreceptor sensitivity in vivo through a COX-dependent mechanism. 
